Intervention not reported
Number of days on therapeutic antibiotics ‐ not reported · treating infections in people with neutropenia or neutrophil dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Number of serious adverse events ‐ pulmonary · treating infections in people with neutropenia or neutrophil dysfunction
It is very uncertain whether the intervention changes number of serious adverse events ‐ pulmonary (very low certainty).
1 finding from 1 review
Intervention not reported
Number of adverse events requiring discontinuation of treatment ‐ not reported · treating infections in people with neutropenia or neutrophil dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Quality of life ‐ not reported · treating infections in people with neutropenia or neutrophil dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
All‐cause mortality up to 30 days · people with neutropenia or neutrophil dysfunction
It is very uncertain whether the intervention changes all‐cause mortality up to 30 days (very low certainty).
1 finding from 1 review
Intervention not reported
Mortality due to infection up to 30 days · people with neutropenia or neutrophil dysfunction
It is very uncertain whether the intervention changes mortality due to infection up to 30 days (very low certainty).
1 finding from 1 review
Intervention not reported
People with localised or systemic bacterial or fungal infections ‐ low‐dose granulocyte transfusions · people with neutropenia or neutrophil dysfunction
It is very uncertain whether the intervention changes people with localised or systemic bacterial or fungal infections ‐… (very low certainty).
1 finding from 1 review
Intervention not reported
People with localised or systemic bacterial or fungal infections ‐ Intermediate‐dose granulocyte transfusions · people with neutropenia or neutrophil dysfunction
The intervention may leads to lower people with localised or systemic bacterial or fungal infections ‐… (low certainty).
1 finding from 1 review
Intervention not reported
People with bacteraemia or fungaemia · people with neutropenia or neutrophil dysfunction
The intervention may leads to lower people with bacteraemia or fungaemia (low certainty).
1 finding from 1 review
Intervention not reported
People with localised bacterial or fungal infection · people with neutropenia or neutrophil dysfunction
It is very uncertain whether the intervention changes people with localised bacterial or fungal infection (very low certainty).
1 finding from 1 review
Intervention not reported
People with serious adverse events · people with neutropenia or neutrophil dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall mortality · people with chemotherapy‐induced febrile neutropenia
Benefits and harms of CSF plus antibiotics showed no clear difference in overall mortality compared with antibiotics alone (low certainty).
1 finding from 1 review
Infection‐related mortality · people with chemotherapy‐induced febrile neutropenia
Benefits and harms of CSF plus antibiotics showed no clear difference in infection‐related mortality compared with antibiotics alone (low certainty).
1 finding from 1 review
People hospitalized for > 10 days · people with chemotherapy‐induced febrile neutropenia
Benefits and harms of CSF plus antibiotics may leads to lower people hospitalized for > 10 days compared with antibiotics alone (low certainty).
1 finding from 1 review
Time to recovery from fever (lower values signify better outcomes) · people with chemotherapy‐induced febrile neutropenia
Benefits and harms of CSF plus antibiotics showed no clear difference in time to recovery from fever (lower values signify better outcomes) compared with antibiotics alone (low certainty).
1 finding from 1 review
Time to withdrawal from ATB (lower values signify better outcomes) · people with chemotherapy‐induced febrile neutropenia
Benefits and harms of CSF plus antibiotics showed no clear difference in time to withdrawal from ATB (lower values signify better outcomes) compared with antibiotics alone (low certainty).
1 finding from 1 review
Deep vein thrombosis · people with chemotherapy‐induced febrile neutropenia
Benefits and harms of CSF plus antibiotics showed no clear difference in deep vein thrombosis compared with antibiotics alone (low certainty).
1 finding from 1 review
All cause mortality · people with cancer who have febrile neutropenia
beta‐lactam monotherapy showed no clear difference in all cause mortality compared with beta‐lactam‐aminoglycoside combination therapy (high certainty).
1 finding from 1 review
Any nephrotoxicity ‐ Ag dosing regimen (Copy) · people with cancer who have febrile neutropenia
beta‐lactam monotherapy leads to lower any nephrotoxicity ‐ Ag dosing regimen (Copy) compared with beta‐lactam‐aminoglycoside combination therapy (high certainty).
1 finding from 1 review
Clinical failure—same beta lactam Antibiotic modifications · people with cancer who have febrile neutropenia
beta‐lactam monotherapy probably leads to higher treatment failure ‐ same beta‐lactam compared with beta‐lactam‐aminoglycoside combination therapy (moderate certainty).
1 finding from 1 review